Welcome to our dedicated page for Icu Medical SEC filings (Ticker: ICUI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ICU Medical, Inc. (Nasdaq: ICUI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, together with AI-powered tools to help interpret them. ICU Medical is a medical technology company headquartered in San Clemente, California, and describes itself as a global leader in infusion systems, infusion consumables and high-value critical care products used in hospital, alternate site and home care settings.
ICU Medical files periodic and current reports with the U.S. Securities and Exchange Commission, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. For example, the company has filed Form 8-K reports to furnish press releases announcing its quarterly financial results. These filings provide detail on total revenues, cost of goods sold, gross profit, operating expenses, product line revenues for Consumables, Infusion Systems and Vital Care, net income or loss, cash flows and non-GAAP measures such as adjusted EBITDA and adjusted diluted earnings per share.
On Stock Titan, AI-generated summaries can highlight key elements of ICU Medical’s filings, helping users quickly understand disclosures related to product line performance, restructuring and integration expenses, contract manufacturing, joint ventures such as Otsuka ICU Medical LLC, and the risk factors the company describes in its Form 10-K and subsequent filings. Real-time updates from EDGAR ensure that new ICUI filings, including Forms 10-K, 10-Q, 8-K and other relevant documents, are added as they become available.
The filings page can also be used to review information that underlies the company’s press releases, such as the 8-K items that reference earnings announcements. By combining official SEC documents with AI explanations, this resource helps investors and analysts navigate ICU Medical’s financial reporting, segment disclosures and regulatory communications without having to manually parse every line of each filing.
Vivek Jain, Chairman and CEO of ICU Medical, reported a Form 4 disclosing transactions dated 09/12/2025. The filing shows a gift of 63,641 shares of common stock to two trusts established for family members who share the same household; the reporting person disclaims beneficial ownership of the shares held by those trusts. After the reported transactions, Mr. Jain retained 66,508 shares directly and the trusts hold 152,339 shares indirectly. The form was signed by an attorney-in-fact on 09/15/2025.
David C. Greenberg, a director of ICU Medical, Inc. (ICUI), reported open-market purchases on 08/27/2025. The Form 4 shows two non-derivative purchases: 602 shares at a weighted-average price of $126.1428, bringing his direct beneficial ownership to 7,362 shares, and 598 shares at a weighted-average price of $126.6895, bringing his direct beneficial ownership to 7,960 shares. The filing also discloses 500 shares held indirectly by a trust. The purchases were executed in multiple transactions within the disclosed price ranges; the filer offers to provide detailed per-transaction pricing on request.
Vivek Jain, Chairman and CEO of ICU Medical, Inc. (ICUI), reported purchases of company common stock on 08/14/2025. He acquired 2,378 shares at a weighted-average price of $112.1165 (purchases ranged $111.75–$112.435) and 19,551 shares at a weighted-average price of $112.9232 (purchases ranged $112.48–$113.435). Following these transactions, Mr. Jain beneficially owns 130,149 shares directly and 88,698 shares indirectly through a trust; a prior direct holding of 110,598 shares is shown prior to the second reported purchase line. The Form 4 was signed by an attorney-in-fact, Paula Darbyshire.
Janus Henderson Group plc and an affiliated fund reported beneficial ownership stakes in ICU Medical, Inc. Janus Henderson Group plc is shown with shared voting and dispositive power over 2,470,146 common shares, equal to 10.0% of the class. Janus Henderson Enterprise Fund reports shared voting and dispositive power over 1,230,753 shares, equal to 5.0% of the class. The filing also notes that JHIUS may be deemed beneficial owner of 2,411,637 shares ( 9.8% ) with shared voting and dispositive authority.
The filing includes a certification that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control. Power of attorney and signature attestations are included, identifying the compliance officer who signed on behalf of the reporting entities.
ICU Medical registered 2,150,000 shares of its common stock for issuance under the Third Amendment to its Amended and Restated 2011 Stock Incentive Plan, approved by stockholders at the 2025 annual meeting on May 13, 2025. The filing confirms these additional shares are the same class as prior awards and incorporates earlier Form S-8 and 10-K registrations by reference, and includes related exhibits and legal opinions.